BPC-157

BPC-157 appears to modulate multiple growth factor pathways — particularly VEGF (vascular endothelial growth factor) and PDGF. Animal studies demonstrate accelerated tendon-to-bone healing, upregulation of growth hormone receptors, cytoprotective effects on the gut lining, and anti-inflammatory properties. The exact mechanism in humans is not established.

Peptide compound — not a steroid, no ester used. Administered by subcutaneous injection or intramuscular injection. Some studies use oral administration for GI-related effects. Short half-life requires daily injection in research protocols.

BPC-157 is used almost exclusively for injury recovery and tissue repair rather than for direct performance enhancement. Athletes with tendon, ligament, or muscle injuries use it because the animal data on accelerated healing is extensive and compelling, and because the alternative of extended time away from training is unacceptable to people with competitive timelines. It is injected either systemically or locally into the site of the injury depending on the application. Some athletes use it prophylactically during high-volume training blocks where injury risk is elevated. Gastrointestinal applications using oral administration for gut health represent a separate use case that is increasingly common among people dealing with gut issues related to high-dose anabolic use.

BPC-157 is not stacked in the traditional sense because it does not function through the androgen receptor and is not part of a hormonal protocol. It is used alongside other compounds rather than in combination with them for synergistic pharmacological effect. Athletes running anabolic stacks add BPC-157 independently for injury recovery or prevention. It is sometimes used with TB-500 in injury recovery protocols because the two peptides are believed to work through complementary mechanisms, with BPC-157 through growth factor pathways and TB-500 through actin regulation.

• No approved human medical use
• Phase I/II trials underway in some regions for IBD
• Extensive preclinical (animal) data for wound healing
• Topical formulation (PL 14736) studied for IBD

• Unknown long-term safety profile — no human trial completion
• Nausea reported with higher doses
• Potential proliferative effects on existing tumors — theoretical concern
• Injection site reactions
• Drug interactions unknown

The primary risk with BPC-157 is not a documented side effect profile, because the human data is too limited to establish one. The primary risk is the absence of knowledge. There are no completed human trials to establish safe dosing ranges, contraindications, or long-term effects. The proliferative mechanism that makes it attractive for healing theoretically applies to all tissues including pre-cancerous ones. The supply chain is entirely unregulated and dose accuracy in research chemical products is highly variable. Local injection into injured tissue by untrained individuals introduces infection and mechanical injury risk.

WADA prohibits all peptide hormones and growth factors. Specific detection methodology for BPC-157 is limited.